TIE1
Summary: This gene encodes a member of the tyrosine protein kinase family. The encoded protein plays a critical role in angiogenesis and blood vessel stability by inhibiting angiopoietin 1 signaling through the endothelial receptor tyrosine kinase Tie2. Ectodomain cleavage of the encoded protein relieves inhibition of Tie2 and is mediated by multiple factors including vascular endothelial growth factor. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2011].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
tyrosine kinase with immunoglobulin like and EGF like domains 1 | MIM:600222 | Ensembl:ENSG00000066056 | HGNC:HGNC:11809 | PA36516 | 1p34.2 |
GO terms in TIE1
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
MF | IBA | GO:0004709 | MAP kinase kinase kinase activity |
MF | IBA | GO:0004713 | protein tyrosine kinase activity |
MF | IBA | GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
MF | IEA | GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
MF | IBA | GO:0004888 | transmembrane signaling receptor activity |
MF | IPI | GO:0005515 | protein binding |
MF | IEA | GO:0005524 | ATP binding |
MF | IBA | GO:0031434 | mitogen-activated protein kinase kinase binding |
CC | IBA | GO:0005737 | cytoplasm |
CC | IBA | GO:0005887 | integral component of plasma membrane |
CC | TAS | GO:0005887 | integral component of plasma membrane |
CC | IBA | GO:0043235 | receptor complex |
BP | IEA | GO:0001525 | angiogenesis |
BP | IEA | GO:0001570 | vasculogenesis |
BP | IEA | GO:0001701 | in utero embryonic development |
BP | TAS | GO:0007165 | signal transduction |
BP | IBA | GO:0007275 | multicellular organism development |
BP | TAS | GO:0007498 | mesoderm development |
BP | IBA | GO:0009968 | negative regulation of signal transduction |
BP | IEA | GO:0016525 | negative regulation of angiogenesis |
BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
BP | IBA | GO:0030154 | cell differentiation |
BP | IEA | GO:0030336 | negative regulation of cell migration |
BP | IEA | GO:0032526 | response to retinoic acid |
BP | IBA | GO:0033674 | positive regulation of kinase activity |
BP | IBA | GO:0043066 | negative regulation of apoptotic process |
BP | IBA | GO:0043410 | positive regulation of MAPK cascade |
BP | IEA | GO:0045026 | plasma membrane fusion |
BP | IBA | GO:0070374 | positive regulation of ERK1 and ERK2 cascade |
Gene expression in normal tissue: TIE1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD506 | Fedratinib | 3 |
iGMDRD780 | PP-30 | 2 |
iGMDRD188 | Piperlongumine | 6 |
iGMDRD399 | Selumetinib | 3 |
iGMDRD23 | Gossypol | 3 |
iGMDRD356 | PNU-74654 | 2 |
iGMDRD524 | ISX-9 | 4 |
iGMDRD64 | Parbendazole | 5 |
iGMDRD260 | FQI-2 | 2 |
iGMDRD52 | Rotenone | 2 |
iGMDRD187 | BRD9876 | 5 |
iGMDRD171 | Pemetrexed | 5 |
iGMDRD61 | Kinetin riboside | 2 |
iGMDRD466 | Chaetocin | 3 |
iGMDRD394 | BX-795 | 3 |
iGMDRD889 | Compound 7d-cis | 3 |
iGMDRD126 | Tipifarnib | 3 |
iGMDRD151 | CHM-1 | 2 |
iGMDRD433 | Lexibulin | 2 |
iGMDRD483 | SCH-529074 | 3 |
iGMDRD781 | Sirolimus | 3 |
iGMDRD546 | BMS-754807 | 3 |
iGMDRD779 | PRL-3 Inhibitor I | 2 |
iGMDRD329 | Merck60 | 5 |
iGMDRD871 | BRD6368 | 2 |
iGMDRD286 | Nsc 632839 | 2 |
iGMDRD322 | FK 866 | 1 |
iGMDRD103 | SN-38 | 2 |
iGMDRD121 | GMX1778 | 2 |
iGMDRD158 | NSC141540 | 4 |
iGMDRD202 | Curcumin | 2 |
iGMDRD137 | Indisulam | 2 |
iGMDRD289 | Parthenolide | 2 |
iGMDRD237 | ABT-751 | 5 |
iGMDRD154 | NSC23766 | 2 |
iGMDRD945 | ML214 | 3 |
iGMDRD123 | Isoevodiamine | 4 |
iGMDRD584 | VER 155008 | 1 |
iGMDRD330 | BRD4132 | 6 |
iGMDRD523 | Cyanoquinoline, 11 | 3 |
iGMDRD79 | Gemcitabine | 6 |
iGMDRD150 | RITA | 3 |
iGMDRD560 | MK-2206 | 2 |
iGMDRD577 | BIX01294 | 3 |
iGMDRD100 | Zebularine | 2 |
iGMDRD268 | Cerulenin | 3 |
iGMDRD451 | Serdemetan | 2 |
iGMDRD60 | Quinoclamine | 1 |
iGMDRD138 | PX 12 | 3 |
iGMDRD885 | Compound 110 | 4 |
iGMDRD870 | BRD63610 | 3 |
iGMDRD193 | Fqi1 | 5 |
iGMDRD446 | LY 2183240 | 1 |
iGMDRD634 | SCHEMBL2608041 | 3 |
iGMDRD359 | OSW-1 | 1 |
iGMDRD280 | CYTOCHALASIN B | 2 |
iGMDRD599 | Salermide | 5 |
iGMDRD772 | BRD4770 | 2 |
iGMDRD1008 | SR-II-138A | 5 |
iGMDRD494 | Neopeltolide | 3 |
iGMDRD144 | NSC95397 | 2 |
iGMDRD414 | MST-312 | 2 |
iGMDRD42 | Vorinostat | 2 |
iGMDRD505 | Pevonedistat | 2 |
iGMDRD246 | NPC26 | 4 |
iGMDRD415 | LE-135 | 2 |
iGMDRD481 | Dactolisib | 3 |
iGMDRD267 | Oligomycin A | 1 |
iGMDRD434 | BMS-536924 | 2 |
iGMDRD351 | GW843682X | 2 |
iGMDRD132 | (-)-gallocatechin-3-O-gallate | 2 |
iGMDRD177 | Teniposide | 6 |
iGMDRD512 | nutlin 3 | 2 |
iGMDRD607 | Ubistatin B | 2 |
iGMDRD424 | Tamatinib | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in TIE1